Morgan Stanley Akari Therapeutics PLC Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.95 - $1.22 $5,262 - $6,757
-5,539 Closed
0 $0
Q1 2022

Oct 27, 2022
BUY
$1.09 - $1.53 $6,037 - $8,474
5,539 New
5,539 $7,000
Q3 2021

Nov 15, 2021
BUY
$1.59 - $1.87 $8,807 - $10,357
5,539 New
5,539 $9,000

About Akari Therapeutics Plc

AKTX Quotes by TradingView
  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $59.3M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email